Hydroxyamphetamine 1% / Tropicamide 0.25% · ophthalmic solution
Mydriatics/Cycloplegics
Approved uses
Mydriasis for diagnostic procedures
One to two drops in the conjunctival sac.
Dilation starts within 15 minutes, peaks by 60 minutes, and most patients recover fully in 6 to 8 hours.
Conditions where short-term pupil dilation is desired
One to two drops in the conjunctival sac.
Dark brown irides dilate more slowly, though one drop dilates adequately at any iris pigmentation.
OFF-LABELNot in the FDA label for this product
Horner syndrome, localising the lesion (single-agent hydroxyamphetamine, not this combination)
The test uses hydroxyamphetamine 1% ALONE. That product is no longer marketed in the United States: hydroxyamphetamine is listed only as a bulk ingredient, and Paremyd adds tropicamide 0.25%, which dilates on its own and so confounds the reading.
n=54 · single agent only
Hydroxyamphetamine releases noradrenaline from an intact third-order neuron, so it separates where cocaine cannot. In 54 patients with Horner syndrome, those with postganglionic damage dilated LESS on the affected side, while almost all with preganglionic lesions dilated MORE. A companion study of 26 normal subjects established the baseline that makes the reading interpretable: a mean 1.96 mm of dilation, and near-symmetric between an individual's two eyes at a mean interocular difference of -0.087 mm, so between-subject variation is much larger than within-subject. Read this row for the pharmacology and the history: the single-agent product it depends on is not available, which is why localization is now usually left to imaging.
Contraindications
- Angle-closure glaucoma, or narrow angles in whom pupil dilation may precipitate an attack.
- Hypersensitivity to any component.
Ophthalmic solution, 15 mL bottle, hydroxyamphetamine hydrobromide 1% / tropicamide 0.25%
Combines hydroxyamphetamine, an indirect sympathomimetic that releases endogenous norepinephrine from intact adrenergic nerve terminals with minimal cycloplegic action, and tropicamide 0.25%, a parasympatholytic blocking the iris sphincter and ciliary muscle; the two act at different effector sites, so the mydriatic effect is additive, and there is evidence with 0.25% tropicamide that full cycloplegia does not occur. Onset within 15 minutes, maximum effect within 60 minutes, dilation and partial cycloplegia lasting 3 hours, and complete recovery in most patients in 6 to 8 hours, though in some cases complete recovery may take up to 24 hours.
Warnings & Precautions
- Angle-closure glaucoma: To avoid inducing angle-closure glaucoma, an estimation of the depth of the angle of the anterior chamber should be made.
- Intraocular pressure elevation: There is evidence that mydriatics may produce a transient rise in patients with open-angle glaucoma; the elderly and others in whom glaucoma or increased intraocular pressure may be encountered following administration should be monitored closely.
- General precautions: Monitor patients with hypertension, hyperthyroidism, diabetes or cardiac disease (arrhythmias or chronic ischemic heart disease) after instillation.
- CNS disturbances: This preparation rarely may cause CNS disturbances which may be particularly dangerous in infants, children or the aged; psychotic reactions, behavioral disturbances and vasomotor or cardio-respiratory collapse have been reported with the use of anticholinergic drugs.
- Not for injection: For topical ophthalmic use only.
Common Side Effects
Increased intraocular pressure has been reported following use of mydriatics. Transient stinging, dryness of the mouth, blurred vision, photophobia with or without corneal staining, tachycardia, headache, allergic reactions, nausea, vomiting, pallor and muscle rigidity have been reported with the use of tropicamide and/or hydroxyamphetamine hydrobromide, and thus may occur with Paremyd. Central nervous system disturbances have also been reported. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse have been reported with the use of anticholinergic drugs. Rare but serious cardiovascular events, including death due to myocardial infarction, ventricular fibrillation and significant hypotensive episodes, have occurred shortly following Paremyd instillation.
Pregnancy: Category C; no animal reproduction studies have been conducted and fetal harm is unknown; give only if clearly needed.
Lactation: Excretion in human milk is unknown; exercise caution in a nursing woman.
Safety and effectiveness in pediatric patients have not been established. Paremyd may rarely cause CNS disturbances which may be dangerous in infants and children, and psychotic reactions, behavioral disturbances and vasomotor or cardio-respiratory collapse in children have been reported with the use of anticholinergic drugs.